1033202-41-3

Basic information

• Product Name: N-(5-Bromo-3-nitropyridin-2-yl)piperidine
• Synonyms: RARECHEM AL BW 0056;TIMTEC-BB SBB004018;P-CHLOROPHENETHYLAMINE;2-(P-CHLOROPHENYL)ETHYLAMINE;2-(4-CHLOROPHENYL)ETHANAMINE;2-(4-CHLOROPHENYL)ETHYLAMINE;1-AMINO-2-(4-CHLOROPHENYL)ETHANE;1-(2-AMINOETHYL)-4-CHLOROBENZENE
• CAS NO: 1033202-41-3
• Molecular Formula: C₁₀H₁₂BrN₃O₂
• Molecular Weight: 286.12518
• EINECS: 205-853-4
• Mol File: 1033202-41-3.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(5-Bromo-3-nitropyridin-2-yl)piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-Bromo-3-nitropyridin-2-yl)piperidine(1033202-41-3)
• EPA Substance Registry System: N-(5-Bromo-3-nitropyridin-2-yl)piperidine(1033202-41-3)

Safety Data

• Hazardous Substances Data: 1033202-41-3(Hazardous Substances Data)

Usage

General Description

N-(5-Bromo-3-nitropyridin-2-yl)piperidine is a chemical compound with the molecular formula C11H13BrN4O2. It is a yellow powder that is primarily used in the synthesis of pharmaceuticals and agrochemicals. N-(5-Bromo-3-nitropyridin-2-yl)piperidine has a piperidine ring, which is a common structural motif found in many pharmaceuticals, and a nitro group, which can be used as a synthetic intermediate in the preparation of various nitrogen-containing organic compounds. The presence of the bromo group also makes it a useful building block for the synthesis of more complex molecules. N-(5-Bromo-3-nitropyridin-2-yl)piperidine is an important intermediate for researchers and chemists in the development of new drugs and agrochemicals.

Upstream product

• 110-89-4 piperidine 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.